Having trouble accessing articles? Reset your cache.

Ocrelizumab: Additional Phase II data

Additional data from an ongoing, 96-week, dose-finding Phase II trial in 220 patients with RRMS showed that 600 and 2,000 mg ocrelizumab significantly reduced the number of

Read the full 272 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE